Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy

Laura Franco, Maurizio Paciaroni, Maria Lotti Enrico, Umberto Scoditti, Francesca Guideri, Alberto Chiti, Alessandro De Vito, Valeria Terruso, Domenico Consoli, Simone Vanni, Alessia Giossi, Giorgia Manina, Cinzia Nitti, Roberta Re, Simona Sacco, Roberto Cappelli, Jan Beyer-Westendorf, Fulvio Pomero, Giancarlo Agnelli, Cecilia Becattini

Research output: Contribution to journalArticle

Abstract

The association between preceding treatment with antiplatelet agents (APs), vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) and mortality after intracerebral hemorrhage (ICH) remains unclear. The aim of this multicenter, prospective cohort study was to assess the risk for death after ICH in consecutive patients who were on treatment with APs, VKAs, DOACs, or no antithrombotic agent. The primary outcome was in-hospital death by day 30. ICH volume at admission and volume expansion were centrally assessed. Out of 598 study patients, in-hospital death occurred in 21% of patients who were on treatment with APs, 25% with VKAs, 30% with DOACs, and 13% with no antithrombotics. Crude death rate was higher in patients on antithrombotics as compared to patients receiving no antithrombotic agent. At multivariate analysis, age (HR 1.07; 95% CI 1.04–1.10), previous stroke (HR 1.83; 95% CI 1.14–2.93), GCS ≤8 at admission (HR 6.06; 95% CI 3.16–9.74) and GCS 9–12 (HR 3.38; 95% CI 1.81–6.33) were independent predictors of death. Treatment with APs (HR 1.29; 95% CI 0.61–2.76), VKAs (HR 1.42; 95% CI 0.70–2.88) or DOACs (HR 1.28; 95% CI 0.61–2.73) were not predictors of death in the overall study population, in non-trauma associated ICH as well as when GCS was not included in the model. ICH volume and volume expansion were independent predictors of death. In conclusion, preceding treatment with antithrombotic is associated with the severity of ICH. Age, previous stroke and clinical severity at presentation were independent predictors of in-hospital death in patients with ICH.

Original languageEnglish
Pages (from-to)35-43
Number of pages9
JournalEuropean Journal of Internal Medicine
Volume75
DOIs
Publication statusPublished - May 2020

Keywords

  • Anticoagulants
  • Antiplatelet agents
  • Cerebral hemorrhage
  • Hematoma
  • Mortality

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy'. Together they form a unique fingerprint.

  • Cite this

    Franco, L., Paciaroni, M., Enrico, M. L., Scoditti, U., Guideri, F., Chiti, A., De Vito, A., Terruso, V., Consoli, D., Vanni, S., Giossi, A., Manina, G., Nitti, C., Re, R., Sacco, S., Cappelli, R., Beyer-Westendorf, J., Pomero, F., Agnelli, G., & Becattini, C. (2020). Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. European Journal of Internal Medicine, 75, 35-43. https://doi.org/10.1016/j.ejim.2019.12.016